Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Context Despite growing evidence that temozolomide (TMZ) therapy is effective for the
treatment of aggressive pituitary tumors (APTs) or carcinomas (PCs), individual therapy …

Context: To date only 18 patients with aggressive pituitary tumors or carcinomas treated with
temozolomide have been reported. Increased expression of O 6-methylguanine-DNA …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years,
presenting aggressive pituitary tumors. In all the patients tested O 6-methylguanine-DNA …

Objective The prognosis of either pituitary carcinoma or aggressive pituitary adenoma
resistant to standard therapies is poor. We assessed the efficacy of treatment with …

Temozolomide is an oral chemotherapy used to treat aggressive pituitary tumours since
2006. It is inexpensive and well tolerated, the main side effects are fatigue, nausea and …

Temozolomide (TMZ) has been shown as an effective treatment option in aggressive
pituitary adenomas and carcinomas. This review analyses the published case series and …

Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …